Celator Pharmaceuticals Inc

Roth Capital analyst Joseph Pantginis weighs in today on Celator Pharmaceuticals Inc (NASDAQ:CPXX), after the biotech company announced that the FDA granted Breakthrough Therapy designation based on the positive Phase III study with Vyxeos, sending shares up over 7% to $16.17.

Pantginis wrote, “This is an important next step for Vyxeos on the path to what we believe is likely approval. The Breakthrough designation provides a significant boost to our confidence that the potential launch timeline provided by the company of mid-2017 will be met or beat. This timeline was based on the company’s assumption that an accelerated path, such as Priority Review would be met. Our CPXX thesis is based on Vyxeos supplanting the standard of care for AML, “7+3″.”

The analyst reiterated a Buy rating on shares of Celator Pharmaceuticals, with a price target of $26, which represents a potential upside of 60% from where the stock is currently trading.

Is it worth listening to this analyst? Check Pantginis’ historical performance and ranking Here.

Spark Therapeutics Inc

Cowen analyst Phil Nadeau reiterated an Outperform rating on shares of Spark Therapeutics Inc (NASDAQ:ONCE), with a price target of $75, after the company announced that new data will be presented on June 11 at the European Hematology Association’s (EHA) 21st Congress. The data will show encouraging initial observations for the first subjects dosed in the Phase 1/2 clinical trial of SPK-9001, the lead investigational compound in the SPK-FIX program, which is being studied for the treatment of Hemophilia B.

Shares of Spark are currently rising over 17% to $48.48 as of 11:10AM EDT.

Nadeau wrote, “Today’s data should increase visibility of the ONCE/PFE hemophilia B gene therapy program and help investors better recognize that Spark’s gene therapy platform has wide applicability. Our DCF analysis indicates that Spark appears undervalued based on SPK-RPE65’s potential alone (est. $65/share). Today’s results provide another viable program in Spark’s pipeline, and therefore another reason to own ONCE.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Phil Nadeau has a yearly average return of 0.6% and a 42% success rate. Nadeau has an average loss of -12% when recommending ONCE, and is ranked #1731 out of 3929 analysts.

Out of the 5 analysts polled by TipRanks, 2 rate Spark Therapeutics stock a Buy, 2 rate the stock a Hold and 1 recommends a Sell. With a return potential of 14%, the stock’s consensus target price stands at $54.60.